Skip to main content

Cerebrovascular risk factors associated with ischemic stroke in a young non-diabetic and non-hypertensive population: a retrospective case-control study

Abstract

Background

Globally, rates of ischemic stroke (IS) have been rising among young adults. This study was designed to identify risk factors associated with IS incidence in young adults unaffected by hypertension or diabetes.

Methods

This was a retrospective case-control study of early-onset IS patients without diabetes and hypertension. Control patients were matched with healthy individuals based upon sex, age (±2 years), and BMI (±3 kg/m2) at a 1:3 ratio. Sociodemographic, clinical, and risk factor-related data pertaining to these patients was collected. The association between these risk factors and IS incidence was then assessed using conditional logistic regression models.

Results

We recruited 60 IS patients and 180 controls with mean ages of 44.37 ± 4.68 and 44.31 ± 4.71 years, respectively, for this study. Relative to controls, IS patients had significantly higher total cholesterol (TG), homocysteine (HCY), white blood cell (WBC), absolute neutrophil count (ANC), systolic blood pressure (SBP), and diastolic blood pressure (DBP) levels, and significantly lower high-density lipoprotein cholesterol (HDL-C) and triglyceride cholesterol (TC), free triiodothyronine (FT3), and free thyroxine (FT4) levels (all P < 0.05). After controlling for potential confounding factors, HCY and ANC were found to be significantly positively associated with IS incidence (OR 1.518, 95%CI 1.165–1.977, P = 0.002 and OR 2.418, 95%CI 1.061–5.511, P = 0.036, respectively), whereas HDL-C and FT3 levels were negatively correlated with IS incidence (OR 0.001, 95%CI 0.000–0.083, P = 0.003 and OR 0.053, 95%CI 0.008–0.326, P = 0.002, respectively).

Conclusions

In young non-diabetic and non-hypertensive patients, lower HDL-C and FT3 levels and higher HCY and ANC levels may be associated with an elevated risk of IS. Additional prospective studies of large patient cohorts will be essential to validate these findings.

Peer Review reports

Background

Ischemic stroke (IS) is a serious condition associated with high morbidity and mortality rates throughout the world. Between 10 and 18% of IS episodes first occur in persons under the age of 50 [1, 2], and such incidence is termed early/young-onset stroke or stroke in young adults [3,4,5]. IS incidence in younger adults can incur high healthcare costs and can significantly decrease labor productivity [6]. As rates of IS among young adults are rising faster than rates among older adults, the global burden associated with this condition is likely to continue rising in the immediate future [7, 8].

Traditionally, risk factors associated with over 80% of IS incidence among young adults include smoking, hypertension, obesity, diabetes, and dyslipidemia,9 with approximately 10 and 35% of these patients being affected by diabetes and hypertension, respectively [9, 10]. Diabetes and its cardiovascular events have a clear inflammatory pathogenesis involved with an adipose-inflammatory vascular axis predisposing to atherosclerosis [11], oxidative stress [12] and atrial fibrillation due to cardiac nervous autonomic dysfunction [13]. Moreover, hypertension can increase the risk of these diabetic vascular complications [14]. Even patients unaffected by these conditions still suffer from IS in some cases, however, with roughly 33% of IS cases in this age group being cryptogenous [15]. Identifying risk factors associated with IS in these patients may facilitate better preventative or interventional treatment. As such, the present study was designed to identify risk factors associated with IS incidence in young adults unaffected by hypertension and diabetes.

Methods

Study design and participants

Between March and October 2019, 60 non-diabetic and non-hypertensive inpatients at Beijing Chao-yang Hospital that had suffered their first-ever incidence of acute IS were recruited for this study (age: 32–50 years). IS as defined as sudden onset neurological dysfunction associated with an infarcted site that was detected via brain magnetic resonance imaging (MRI). A healthy control population that was matched according to age (±2-years), sex, and BMI (±3.0 kg/m2) were recruited randomly from among patients undergoing physical examinations at our hospital. Recruitment was conducted at a 1:3 case to control ratio. Patients were excluded from this study if they suffered from known hypertension, diabetes, cancer, autoimmunity, thyroid disease, encephalitis, head trauma, cerebral hemorrhage, severe multiple organ dysfunction, infections, severe liver or kidney diseases, or pregnancy. The Medical Ethics Committee of Beijing Chaoyang Hospital approved this study, which was consistent with the Declaration of Helsinki, and the requirement for written informed consent was waived due to the retrospective design. Patient data have been de-identified upon data collection.

Measurements

For all patients, the following data were recorded: sex, age, BMI, smoking status, SBP, DBP, fasting blood glucose (FBG), creatinine (CR), uric acid (UA), HCY, TC, TG, HDL-C, low-density lipoprotein cholesterol (LDL-C), FT3, FT4, and thyroid-stimulating hormone (TSH) levels, as well as WBC, ANC, absolute lymphocyte count (ALC), platelet (PLT), and hemoglobin (HGB) values. All IS patients underwent routine testing include brain MRI scans, chest X-ray, and cardiac tests including electrocardiography and transthoracic echocardiograms in an effort to detect any potential atrial fibrillation, ischemic heart disease, or rheumatic heart disease. Other testing was conducted as appropriate in order to ensure that patients met with study inclusion/exclusion criteria.

Following overnight fasting, blood samples were collected from the antecubital vein of each patient and were analyzed with an Abbott Architect i2000 (Abbott Diagnostics, IL, USA). The same medical staff measured the weight and height of all patients, and BMI (in kg/m2) was calculated based on these values. The same 3.0 T Siemens scanner (Erlangen, Germany) was used for all MRI scans.

Statistical analysis

SPSS 24.0 (SPSS, IL, USA) was used for all statistical testing. The Kolmogorov-Smirnov test was used to assess the normality of distributed data, with normally and non-normally distributed data being expressed as means ± standard deviation (SD) and medians with interquartile ranges (IQR). Data were compared between case and control groups using chi-squared tests, Student’s t-tests, or Mann-Whitney U tests as appropriate, and univariate odds ratios (ORs) for these risk factors were calculated. Those risk factors that were significantly associated with IS incidence in univariate analyses were then incorporated into a multivariate conditional logistic regression model, after which adjusted ORs and 95% confidence intervals were estimated. For this model, a forward stepwise logistic regression approach with a P < 0.10 variable removal level was used. A two-sided P < 0.05 was the significance threshold for this study.

Results

Patient baseline characteristics

Baseline data pertaining to the control and IS patient groups in this study are compiled in Table 1. In total, 51/60 IS patients were male, a history of cigarette smoking was reported in 68.3% of these patients, and the mean age at time of stroke was 44.31 ± 4.71 years. There were no significant differences in age, sex, or BMI between these two patient groups, nor were any differences detected in serum TSH, LDL-C, FBG, CR, UA, ALC, HGB, or PLT when comparing these groups (all P > 0.05). However, IS patients exhibited significantly lower HDL-C and TC levels relative to controls [0.95 (0.62–1.59) vs. 1.16 (0.69–2.29) mmol/L, 4.39 ± 1.08 vs. 4.97 ± 0.78 mmol/L, respectively, P < 0.001]. Levels of serum FT3 and FT4 were also significantly lower in IS patients relative to controls, while TG, HCY, WBC, ANC, SBP, and DBP values were all significantly elevated among IS patients (all P < 0 .05).

Table 1 The baseline characteristics of the control and IS groups

Identification of risk factors associated with early-onset IS

Univariate logistic regression analyses were initially used to identify risk factors associated with IS incidence (Table 2), revealing FT3, FT4, HDL-C, TC, TG, HCY, WBC, ANC, PLT, SBP, and DBP values to all be significantly associated with such incidence. Subsequent multivariate conditional logistic regression analysis revealed that HDL-C, FT3, HCY, and ANC levels were all independently associated with IS risk (Table 3). Both HCY and ANC levels were positively correlated with IS incidence with respective ORs of 1.518 (95%CI 1.165–1.977, P = 0.002) and 2.418 (95%CI 1.061–5.511, P = 0.036). In contrast, HDL-C and FT3 levels were significantly negatively correlated with IS rates (OR 0.001, 95%CI 0.000–0.083, P = 0.003 and OR 0.053, 95%CI 0.008–0.326, P = 0.002, respectively).

Table 2 Univariate logistic regression model of risk factors for IS in non-diabetic and non-hypertensive young population
Table 3 Multivariable conditional logistic regression model of risk factors for IS in non-diabetic and non-hypertensive young population

Discussion

Herein, we evaluated risk factors for early-onset IS among non-diabetic non-hypertensive patients. We found that IS patients exhibited elevated TG, HCY, WBC, ANC, SBP, and DBP levels, as well as lower HDL-C, TC, FT3, and FT4 levels relative to controls. Further analysis revealed that HCY and ANC levels were positively correlated with IS risk, whereas HDL-C and FT3 levels were negatively correlated with such risk.

Our findings are consistent with those of many other prior analyses which have detected negative correlations between HDL-C levels and IS incidence in young adults. Indeed, while low HDL-C has been linked to elevated IS risk in young populations, LDL-C, TG, and TC levels have been found to be unrelated to such risk [16,17,18]. These findings are not universal, however, as no significant relationship between HDL-C levels and IS was observed in the ARIC Study [19]. Indeed, some studies have found HDL-C levels to be negatively correlated with vascular events and mortality among IS patients [20, 21], and one study found elevated HDL-C levels to be correlated with decreased IS severity in patients ≤50 years old, whereas no such relationship was observed among older patients [22]. HDL-C is involved in reverse cholesterol transport, but also plays antithrombotic and anti-inflammatory roles [23, 24]. In one systematic review, the risk of IS was found to decrease by 11–15% for every 10 mg/dL increase in HDL-C [25]. HDL administration has also been found to be neuroprotective, as it is associated with reducing neutrophil recruitment and preserving the blood-brain barrier [26]. Based on our data and these prior studies, we can hypothesize that HDL-C play a key role in mediating IS risk among younger patients, and that preventative efforts aimed at elevating serum HDL-C levels in younger adults may significantly decrease IS risk.

We also found that FT3 levels were negatively correlated with IS incidence among young adults. This is the first study to our knowledge to have reported such a relationship, as prior studies and meta-analysis have largely focused on correlations between low FT3 levels and severity/mortality among acute IS patients [27,28,29,30,31]. These prior studies have reported such a relationship even for low FT3 values within the standard reference range [32, 33]. One study, however, found that this relationship was age-dependent, such that TT3 and FT3 levels were unrelated to IS outcomes in patients < 65 years old, whereas TT3 levels were independently predictive of poor outcomes among older patients [34]. In these prior studies, the average population ages ranged from 61.4–81.5 years [27,28,29,30,31,32], with the exception of one study with a median population age of 48 years [33]. Serum TT3 and FT3 levels are lower among healthy older individuals [35], and FT3 levels decline over time [36]. Age may, therefore, have the potential to confound the effect of FT3 on the cardiovascular system in older individuals, whereas lower FT3 levels in younger patients may be more clinically significant. Triiodothyronine (T3) has been shown neuroprotective effects with a possible mechanism of activation of nitric oxide signaling and vasodilation [37, 38]. Moreover, T3 modulates reorganization of neuronal circuits and synaptic plasticity, motor recovery and functional connectivity during critical periods of recovery after stroke [39]. T3 administration may reduce infarct volume and related edema through the inhibition of aquaporin-4 expression in perimicrovascular astrocytic endfeet [37, 40]. As acute diseases can decrease the conversion of FT4 to FT3 [41], reductions in FT3 levels in acute IS patients may simply be indicative of disease rather than a driver of disease progression. Future research will be essential in order to confirm the mechanistic basis for the observed correlation.

We additionally found that HCY levels were positively correlated with early-onset IS risk. Hyperhomocysteinemia is well known to be associated with elevated IS risk [42]. In line with our findings, many prior studies have confirmed elevated HCY levels to be associated with IS risk in younger patient populations [43,44,45,46], with this correlation being strongest in younger individuals [43]. The risk of IS has been shown to be roughly two-fold higher in IS patients with high HCY levels relative to patients with low HCY levels [47, 48]. Huang et al. in contrast, determined a 20% reduction in HCY level to be linked with a 7% decrease in IS risk [49]. HCY levels are also correlated with stroke severity, with a poorer prognosis [50, 51], and with stroke recurrence [52]. A 3 μmol/L decrease in total HCY levels was associated with a 10% reduction in the risk of stroke recurrence [53]. HCY may elevate the risk of IS incidence through mechanisms including the impairment of thrombolysis, thrombosis, enhanced H2O2 production, endothelial dysfunction, and increased LDL-C oxidation [54,55,56]. HCY, also, can favor atrial fibrillation occurrence and a subsequent IS (particularly in cardioembolic and cryptogenic strokes) by inducing an electrical and structural atrial remodelling [57, 58].

We also found ANC levels to be positively correlated with early-onset IS risk, in line with prior reports that ANC is an independent predictor of IS incidence and recurrence [59,60,61]. Other studies have also found elevated ANC values to be related to more severe stroke, poorer stroke outcomes, larger infarct volumes [62, 63], the presence of intracranial atherosclerotic stenosis [64], and unstable carotid plaques [65]. Neutrophils can influence thrombosis and atherosclerosis, thereby modulating the risk of IS [66, 67]. Neutrophil activation can be reduced by elevated levels of HDL-C and consequent changes in pro-inflammatory cytokine production [68], partially explaining the beneficial impact of HDL-C levels in this context. Neutrophils are key markers of acute inflammation, and are among the first cells recruited following IS [66]. Whether neutrophil accumulation is a response to stroke or a risk factor associated with IS incidence thus requires further investigation.

This study has multiple limitations compared with previous studies that younger strokes showed higher frequency of alcohol abuse, heavy smoking, obesity [69] and physical activity provided metabolic and anti-inflammatory properties [70]. For one, we were not able to account for all possible risk factors pertaining to IS incidence (including nutrition, alcohol intake, and physical inactivity) in this patient population owing to a lack of complete data. For another, we had not evaluated risk factors being influenced by IS subtype (e.g. TOAST classification [71]) distribution for lacking of complete subtypes data. It would be useful to assess the differences among subtypes of IS, particularly between cardioembolic and non-cardioembolic infarction because cardioembolic stroke is the subtype of IS with the highest in-hospital mortality and poor short-term prognosis [72]. Furthermore, we selected controls at random from among health patients, resulting in significant differences in rates of cigarette smoking between the case and control populations that may have significantly impacted the results of our analyses. This was also a retrospective single-center study with a small sample size, potentially biasing our results. Despite these limitations, we believe that these data represent a valuable first step towards understanding risk factors associated with early-onset IS incidence among non-hypertensive and non-diabetic patients.

Conclusions

Rates of early-onset IS among non-hypertensive non-diabetic patients are rising globally. One of the future lines of research in the study of IS in young people would be its relationship with cerebrovascular risk factors. Our results suggest that HCY and ANC levels are positively correlated with the risk of early-onset IS, whereas HDL-C and FT3 levels were negatively correlated with such risk. These results provide a valuable framework for future research aimed at understanding how controlling these risk factors may prevent or reduce the risk of IS in younger populations.

Availability of data and materials

The data in this study are available from the corresponding author upon reasonable request.

References

  1. 1.

    Kissela BM, Khoury JC, Alwell K, Moomaw CJ, Woo D, Adeoye O, et al. Age at stroke: temporal trends in stroke incidence in a large, biracial population. Neurology. 2012;79:1781–7.

    PubMed  PubMed Central  Article  Google Scholar 

  2. 2.

    Singhal AB, Biller J, Elkind MS, Fullerton HJ, Jauch EC, Kittner SJ, et al. Recognition and management of stroke in young adults and adolescents. Neurology. 2013;81:1089–97.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  3. 3.

    Siriratnam P, Godfrey A, O'Connor E, Pearce D, Hu CC, Low A, et al. Prevalence and risk factors of ischaemic stroke in the young: a regional Australian perspective. Intern Med J. 2020;50(6):698–704.

    PubMed  Article  PubMed Central  Google Scholar 

  4. 4.

    Ekker MS, Boot EM, Singhal AB, Tan KS, Debette S, Tuladhar AM, et al. Epidemiology, aetiology, and management of ischaemic stroke in young adults. Lancet Neurol. 2018;17:790–801.

    PubMed  Article  PubMed Central  Google Scholar 

  5. 5.

    Maaijwee NA, Rutten-Jacobs LC, Schaapsmeerders P, van Dijk EJ, de Leeuw FE. Ischaemic stroke in young adults: risk factors and long-term consequences. Nat Rev Neurol. 2014;10:315–25.

    PubMed  Article  PubMed Central  Google Scholar 

  6. 6.

    Maaijwee NA, Rutten-Jacobs LC, Arntz RM, Schaapsmeerders P, Schoonderwaldt HC, van Dijk EJ, et al. Long-term increased risk of unemployment after young stroke: a long-term follow-up study. Neurology. 2014;83:1132–8.

    PubMed  Article  PubMed Central  Google Scholar 

  7. 7.

    Ekker MS, Verhoeven JI, Vaartjes I, van Nieuwenhuizen KM, Klijn CJM, de Leeuw FE. Stroke incidence in young adults according to age, subtype, sex, and time trends. Neurology. 2019;92(21):e2444–54.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  8. 8.

    Vangen-Lonne AM, Wilsgaard T, Johnsen SH, Carlsson M, Mathiesen EB. Time trends in incidence and case fatality of ischemic stroke: the tromso study 1977–2010. Stroke. 2015;46:1173–9.

    PubMed  Article  PubMed Central  Google Scholar 

  9. 9.

    Aigner A, Grittner U, Rolfs A, Norrving B, Siegerink B, Busch MA. Contribution of established stroke risk factors to the burden of stroke in young adults. Stroke. 2017;48:1744–51.

    PubMed  Article  PubMed Central  Google Scholar 

  10. 10.

    Boot E, Ekker MS, Putaala J, Kittner S, De Leeuw FE, Tuladhar AM. Ischaemic stroke in young adults: a global perspective. J Neurol Neurosurg Psychiatry. 2020;91(4):411–7.

    PubMed  Article  PubMed Central  Google Scholar 

  11. 11.

    Tuttolomondo A, Maida C, Pinto A. Diabetic foot syndrome: immune-inflammatory features as possible cardiovascular markers in diabetes. World J Orthop. 2015;6(1):62–76.

    PubMed  PubMed Central  Article  Google Scholar 

  12. 12.

    Xu YJ, Tappia PS, Neki NS, Dhalla NS. Prevention of diabetes-induced cardiovascular complications upon treatment with antioxidants. Heart Fail Rev. 2014;19(1):113–21.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  13. 13.

    G, Fava I, Petrella A, Barbieri M, Paolisso G. Cryptogenic stroke and diabetes: a probable link between silent atrial fibrillation episodes and cerebrovascular disease. Expert Rev Cardiovasc Ther. 2014;12(3):323–9.

    Article  CAS  Google Scholar 

  14. 14.

    Tuttolomondo A, Maida C, Pinto A. Diabetic foot syndrome as a possible cardiovascular marker in diabetic patients. J Diabetes Res. 2015;2015:268390.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  15. 15.

    Pirastehfar M, Katz P, Gentile NT, Jacobi JE, Linares G. Abstract WP208: incidence of ischemic stroke in young adults, a 4 year retrospective review from an urban tertiary Care Center in North Philadelphia. Stroke. 2016;47:AWP208.

    Google Scholar 

  16. 16.

    Lipska K, Sylaja PN, Sarma PS, Thankappan KR, Kutty VR, Vasan RS, et al. Risk factors for acute ischaemic stroke in young adults in South India. J Neurol Neurosurg Psychiatry. 2007;78:959–63.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  17. 17.

    Albucher JF, Ferrieres J, Ruidavets JB, Guiraud-Chaumeil B, Perret BP, Chollet F. Serum lipids in young patients with ischaemic stroke: a case-control study. J Neurol Neurosurg Psychiatry. 2000;69:29–33.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  18. 18.

    Kivioja R, Pietilä A, Martinez-Majander N, Gordin D, Havulinna AS, Salomaa V, et al. Risk factors for early-onset ischemic stroke: a case-control study. J Am Heart Assoc. 2018;7(21):e009774.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  19. 19.

    Shahar E, Chambless LE, Rosamond WD, Boland LL, Ballantyne CM, McGovern PG, et al. Plasma lipid profile and incident ischemic stroke: the atherosclerosis risk in communities (ARIC) study. Stroke. 2003;34:623–31.

    PubMed  Article  PubMed Central  Google Scholar 

  20. 20.

    Yeh PS, Yang CM, Lin SH, Wang WM, Chen PS, Chao TH, et al. Low levels of high-density lipoprotein cholesterol in patients with atherosclerotic stroke: a prospective cohort study. Atherosclerosis. 2013;228:472–7.

    CAS  PubMed  Article  Google Scholar 

  21. 21.

    Mei L, Fang X, Mu L, Liu H, Zhang H, Qin X, et al. Association of serum high density lipoprotein cholesterol level and risk of recurrent ischemic stroke. Zhonghua Xin Xue Guan Bing Za Zhi. 2014;42:295–300.

    CAS  PubMed  Google Scholar 

  22. 22.

    Sanossian N, Saver JL, Kim D, Razinia T, Ovbiagele B. Do high-density lipoprotein cholesterol levels influence stroke severity ? J Stroke Cerebrovasc Dis. 2006;15(5):187–9.

    PubMed  Article  Google Scholar 

  23. 23.

    Van der Stoep M, Korporaal SJ, Van Eck M. High-density lipoprotein as a modulator of latelet and coagulation responses. Cardiovasc Res. 2014;103:362–71.

    PubMed  Article  CAS  Google Scholar 

  24. 24.

    Kerry-Anne R. Barter Philip J. Cardioprotective functions of HDLs. J Lipid Res. 2014;55:168–79.

    Article  CAS  Google Scholar 

  25. 25.

    Amarenco P, Labreuche J, Touboul PJ. High-density lipoprotein-cholesterol and risk of stroke and carotid atherosclerosis: a systematic review. Atherosclerosis. 2008;196:489–96.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  26. 26.

    Lapergue B, Moreno JA, Dang BQ, Coutard M, Delbosc S, Raphaeli G, et al. Protective effect of high-density lipoprotein-based therapy in a model of embolic stroke. Stroke. 2010;41(7):1536–42.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  27. 27.

    Suda S, Shimoyama T, Nagai K, Arakawa M, Aoki J, Kanamaru T, et al. Low free Triiodothyronine predicts 3-month poor outcome after acute stroke. J Stroke Cerebrovasc Dis. 2018;27(10):2804–9.

    PubMed  Article  PubMed Central  Google Scholar 

  28. 28.

    Taroza S, Rastenytė D, Podlipskytė A, Kazlauskas H, Mickuvienė N. Nonthyroidal illness syndrome in Ischaemic stroke patients is associated with increased mortality. Exp Clin Endocrinol Diabetes. 2019. https://doi.org/10.1055/a-0915-2015.

  29. 29.

    Zhang S, Zhao X, Xu S, Yuan J, Si Z, Yang Y, et al. Low free triiodothyronineis predicts worsen neurological outcome of patients with acute ischemic stroke: a retrospective study with bioinformatics analysis. BMC Neurol. 2019;19(1):272.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  30. 30.

    Jiang X, Xing H, Wu J, Du R, Liu H, Chen J, et al. Prognostic value of thyroid hormones in acute ischemic stroke - a meta analysis. Sci Rep. 2017;7(1):16256.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  31. 31.

    Lamba N, Liu C, Zaidi H, Broekman MLD, Simjian R, Shi C, et al. A prognostic role for low triiodothyronine syndrome in acute stroke patients: a systematic review and meta-analysis. Clin Neurol Neurosurg. 2018;169:55–63.

    PubMed  Article  PubMed Central  Google Scholar 

  32. 32.

    Suda S, Muraga K, Kanamaru T, Okubo S, Abe A, Aoki J, et al. Low free triiodothyronine predicts poor functional outcome after acute ischemic stroke. J Neurol Sci. 2016;368:89–93.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  33. 33.

    Feng X, Zhou X, Yu F, Liu Z, Wang J, Li Z, et al. Low-normal free triiodothyronine and high leukocyte levels in relation to stroke severity and poor outcome in acute ischemic stroke with intracranial atherosclerotic stenosis. Int J Neurosci. 2019;129(7):635–41.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  34. 34.

    Li LQ, Xu XY, Li WY, Hu X-Y, Lv W. The prognostic value of total T3 after acute cerebral infarction is age-dependent: a retrospective study on 768 patients. BMC Neurol. 2019;19(1):54.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  35. 35.

    van den Beld AW, Visser TJ, Feelders RA, Grobbee DE, Lamberts SW. Thyroid hormone concentrations, disease, physical function, and mortality in elderly men. J Clin Endocrinol Metab. 2005;90(12):6403–9.

    PubMed  Article  CAS  PubMed Central  Google Scholar 

  36. 36.

    Strich D, Karavani G, Edri S, Chay C, Gillis D. FT3 is higher in MALES THAN in FEMALES and decreases OVER the lifespan. Endocr Pract. 2017;23(7):803–7.

    PubMed  Article  PubMed Central  Google Scholar 

  37. 37.

    Mdzinarishvili A, Sutariya V, Talasila PK, Geldenhuys WJ, Sadana P. Engineering triiodothyronine (T3) nanoparticle for use in ischemic brain stroke. Drug Deliv Transl Res. 2013;3(4):309–17.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  38. 38.

    Sayre NL, Sifuentes M, Holstein D, Cheng SY, Zhu X, Lechleiter JD. Stimulation of astrocyte fatty acid oxidation by thyroid hormone is protective against ischemic stroke-induced damage. J Cereb Blood Flow Metab. 2017;37(2):514–27.

    PubMed  Article  PubMed Central  Google Scholar 

  39. 39.

    Talhada D, Feiteiro J, Costa AR, Talhada T, Cairrão E, Wieloch T, et al. Triiodothyronine modulates neuronal plasticity mechanisms to enhance functional outcome after stroke. Acta Neuropathol Commun. 2019;7(1):216.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  40. 40.

    Sadana P, Coughlin L, Burke J, Woods R, Mdzinarishvili A. Anti-edema action of thyroid hormone in MCAO model of ischemic brain stroke: possible association with AQP4 modulation. J Neurol Sci. 2015;354(1–2):37–45.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  41. 41.

    Wu G-H, Kong F-Z, Cheng Q-Z, Luo W-F, Du X-D. Low T3 syndrome predicts severe neurological deficits of cerebral infarction inpatients with large artery artherosclerosis in internal carotid artery system. Neuro Endocrinol Lett. 2014;35:149–53.

    CAS  PubMed  PubMed Central  Google Scholar 

  42. 42.

    Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(7):2160–236.

    PubMed  Article  PubMed Central  Google Scholar 

  43. 43.

    Li CJ, Du XX, Yang K, Song LP, Li PK, Wang Q, et al. Effects of professional rehabilitation training on the recovery of neurological function in young stroke patients. Neural Regen Res. 2016;11(11):1766–72.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  44. 44.

    Toyoda K, Uwatoko T, Shimada T, Hagiwara N, Fujimoto S, Ibayashi S, et al. Recurrent small-artery disease in hyperhomocysteinemia: widowers' stroke syndrome? Intern Med. 2004;43(9):869–72.

    PubMed  Article  PubMed Central  Google Scholar 

  45. 45.

    Madonna P, de Stefano V, Coppola A, Cirillo F, Cerbone AM, Orefice G, et al. Hyperhomocysteinemia and other inherited prothrombotic conditions in young adults with a history of ischemic stroke. Stroke. 2002;33:51–6.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  46. 46.

    Zhang S, Chang C, Zhang J, Song B, Xu Y. Reconsideration for ischemic stroke risk factors in youth. Zhonghua Yi Xue Za Zhi. 2014;94(25):1936–40.

    PubMed  PubMed Central  Google Scholar 

  47. 47.

    Han L, Wu Q, Wang C, Hao Y, Zhao J, Zhang L, et al. Homocysteine, ischemic stroke, and coronary heart disease in hypertensive patients: a population-based, prospective cohort study. Stroke. 2015;46:1777–86.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  48. 48.

    Wang L, Shen J, Chen CX, Chen ZB, Shen XJ, Song YJ, et al. The association between homocysteine and the different ischemic stroke subtypes: a meta-analysis. Chin J Gerontol. 2018;38:2052–5.

    Google Scholar 

  49. 49.

    Huang X, Li Y, Li P, Li J, Bao H, Zhang Y, et al. Association between percent decline in serum total homocysteine and risk of first stroke. Neurology. 2017;89:2101–7.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  50. 50.

    Shi Z, Guan Y, Huo YR, Liu S, Zhang M, Lu H, et al. Elevatedtotal homocysteine levels in acute ischemic stroke are associated with long-term mortality. Stroke. 2015;46(9):2419–25.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  51. 51.

    Kwon HM, Lee YS, Bae HJ, Kang DW. Homocysteine as a predictor of early neurological deterioration in acute ischemic stroke. Stroke. 2014;45(3):871–3.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  52. 52.

    Kumral E, Saruhan G, Aktert D, et al. Association of hyperhomocysteinemia with stroke recurrence after initial stroke. J Stroke Cerebrovasc Dis. 2016;25(8):2047–54.

    PubMed  Article  PubMed Central  Google Scholar 

  53. 53.

    Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the vitamin intervention for stroke prevention (VISP) randomized controlled trial. JAMA. 2004;291:565–75.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  54. 54.

    Pushpakumar S, Kundu S, Sen U. Endothelial dysfunction: the link between homocysteine and hydrogen sulfide. Curr Med Chem. 2014;21:3662–72.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  55. 55.

    Faraci FM, Lentz SR. Hyperhomocysteinemia, oxidative stress, and cerebral vascular dysfunction. Stroke. 2004;35:345–7.

    PubMed  Article  PubMed Central  Google Scholar 

  56. 56.

    Antoniades C, Antonopoulos AS, Tousoulis D, Marinou K, Stefanadis C. Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials. Eur Heart J. 2009;30:6–15.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  57. 57.

    Acampa M, Lazzerini PE, Martini G. Postoperative atrial fibrillation and ischemic stroke: the role of homocysteine. Eur Stroke J. 2018;3(1):92–3.

    PubMed  Article  PubMed Central  Google Scholar 

  58. 58.

    Acampa M, Lazzerini PE, Guideri F, Tassi R, Martini G. Ischemic stroke after heart transplantation. J Stroke. 2016;18(2):157–68.

    PubMed  PubMed Central  Article  Google Scholar 

  59. 59.

    Wu TH, Chien KL, Lin HJ, Hsu HC, Su TC, Chen MF, et al. Total white blood cell count or neutrophil count predict ischemic stroke events among adult Taiwanese: report from a community-based cohort study. BMC Neurol. 2013;13:7.

    PubMed  PubMed Central  Article  Google Scholar 

  60. 60.

    Zia E, Melander O, Bjorkbacka H, Hedblad B, Engström G. Total and differential leucocyte counts in relation to incidence of stroke subtypes and mortality: a prospective cohort study. J Intern Med. 2012;272:298–304.

    CAS  PubMed  Article  Google Scholar 

  61. 61.

    Grau AJ, Boddy AW, Dukovic DA, Buggle F, Lichy C, Brandt T, et al. Leukocyte count as an independent predictor of recurrent ischemic events. Stroke. 2004;35(5):1147–52.

    PubMed  Article  Google Scholar 

  62. 62.

    Kim J, Song TJ, Park JH, Lee HS, Nam CM, Nam HS, et al. Different prognostic value of white blood cell subtypes in patients with acute cerebral infarction. Atherosclerosis. 2012;222:464–7.

    CAS  PubMed  Article  Google Scholar 

  63. 63.

    Cui LL, Zhang Y, Chen ZY, Su Y-Y, Liu Y, Boltze J. Early neutrophil count relates to infarct size and fatal outcome after large hemispheric infarction. CNS Neurosci Ther. 2020;26(8):829–36.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  64. 64.

    Zhang X, Hou X-H, Ma Y-H, Shen X-N, Cao X-P, Song J-H, et al. Association of peripheral neutrophil count with intracranial atherosclerotic stenosis. BMC Neurol. 2020;20(1):65.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  65. 65.

    Nasr N, Ruidavets JB, Arnal JF, Sie P, Larrue V. Association of neutrophil count with microembolization in patients with symptomatic carotid artery stenosis. Atherosclerosis. 2009;207:519–23.

    CAS  PubMed  Article  Google Scholar 

  66. 66.

    Jickling GC, Liu D, Ander BP, Stamova B, Zhan X, Sharp FR. Targeting neutrophils in ischemic stroke: translational insights from experimental studies. J Cereb Blood Flow Metab. 2015;35(6):888–901.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  67. 67.

    Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473:317–25.

    CAS  PubMed  Article  Google Scholar 

  68. 68.

    Carbone F, Nencioni A, Mach F, Vuilleumier N, Montecucco F. Pathophysiological role of neutrophils in acute myocardial infarction. Thromb Haemost. 2013;110(3):501–14.

    CAS  PubMed  Article  Google Scholar 

  69. 69.

    Arboix A, Estevez S, Rouco R, Oliveres M, García-Eroles L, Massons J. Clinical characteristics of acute lacunar stroke in young adults. Expert Rev Neurother. 2015;15(7):825–31.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  70. 70.

    Di Raimondo D, Tuttolomondo A, Buttà C, Casuccio A, Giarrusso L, Miceli G, et al. Metabolic and anti-inflammatory effects of a home-based programme of aerobic physical exercise. Int J Clin Pract. 2013;67(12):1247–53.

    PubMed  Article  CAS  PubMed Central  Google Scholar 

  71. 71.

    Pinto A, Tuttolomondo A, Di Raimondo D, Fernandez P, Licata G. Risk factors profile and clinical outcome of ischemic stroke patients admitted in a Department of Internal Medicine and classified by TOAST classification. Int Angiol. 2006;25(3):261–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  72. 72.

    Arboix A, Alió J. Acute cardioembolic stroke: an update. Expert Rev Cardiovasc Ther. 2011;9(3):367–79.

    PubMed  Article  PubMed Central  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

This work was supported by grants from the Chinese National Natural Science Foundation (No. 81770792) and Key Projects of Science and Technology Planning of Beijing Municipal Education Commission (KZ201810025038) to G.W.; and the Beijing Talents foundation (2018–12) to J.L.

Author information

Affiliations

Authors

Contributions

Conceived and designed the experiments: JL GW. Performed the experiments: NZ LZ QW JZ. Analyzed the data: NZ JL GW. Wrote the paper: NZ JL GW. The author(s) read and approved the final manuscript.

Authors’ information

Not applicable.

Corresponding authors

Correspondence to Jia Liu or Guang Wang.

Ethics declarations

Ethics approval and consent to participate

The Medical Ethics Committee of Beijing Chaoyang Hospital approved this study, which was consistent with the Declaration of Helsinki, and the requirement for written informed consent was waived due to the retrospective design. Patient data have been de-identified upon data collection.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Zhang, N., Zhang, L., Wang, Q. et al. Cerebrovascular risk factors associated with ischemic stroke in a young non-diabetic and non-hypertensive population: a retrospective case-control study. BMC Neurol 20, 424 (2020). https://doi.org/10.1186/s12883-020-02005-7

Download citation

Keywords

  • Ischemic stroke
  • Risk factors
  • Young adults
  • Early-onset
  • Young-onset